ACZONE (dapsone) by Almirall. Approved for sulfone [epc]. First approved in 2016.
Drug data last refreshed 14h ago · AI intelligence enriched 3d ago
ACZONE (dapsone) is a topical gel sulfone antibiotic approved in 2016 for acne treatment. It works by reducing bacterial colonization and inflammatory responses in acne lesions. The drug is applied directly to affected skin areas.
Product is at peak lifecycle stage with minimal claims volume, suggesting a niche, stable positioning with modest commercial footprint.
Sulfone
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Phototoxicity Test of Dapsone Gel in Healthy Volunteers
Photoallergy Potential of Dapsone Gel in Healthy Volunteers
Dermal Tolerability of Dapsone Gel in Healthy Volunteers
A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris
Worked on ACZONE at Almirall? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ACZONE offers exposure to niche dermatology market management during a stable, mature product lifecycle. The approaching LOE and modest commercial footprint suggest roles focus on maximizing value retention and supporting lifecycle extension rather than significant growth.